[1] HATFULL G F, HENDRIX R W. Bacteriophages and their genomes[J]. Current Opin Virol, 2011, 1(4):298-303.
[2] FISCHBACH M A, WALSH C T. Antibiotics for emerging pathogens[J]. Science, 2009, 325(5944):1089-1093.
[3] HARDS K, COOK G M. Targeting bacterial energetics to produce new antimicrobials[J]. Drug Resist Updat, 2018, 36:1-12.
[4] REARDON S. Phage therapy gets revitalized:The rise of antibiotic resistance rekindles interest in a century-old virus treatment[J]. Nature, 2014, 510(7503):15-16.
[5] CRISCUOLO E, SPADINI S, LAMANNA J, et al. Bacteriophages and their immunological applications against infectious threats[J]. J Immunol Res, 2017, 2017:3780697.
[6] XU Y Q, LIU Y, LIU Y, et al. Bacteriophage therapy against Enterobacteriaceae[J]. Virol Sin, 2015, 30(1):11-18.
[7] OFIR G, SOREK R. Contemporary phage biology:From classic models to new insights[J]. Cell, 2018, 172(6):1260-1270.
[8] BARTUAL S G, OTERO J M, GARCIA-DOVAL C, et al. Structure of the bacteriophage T4 long tail fiber receptor-binding tip[J]. Proc Natl Acad Sci U S A, 2010, 107(47):20287-20292.
[9] LEIMAN P G, ARISAKA F, VAN RAAIJ M J, et al. Morphogenesis of the T4 tail and tail fibers[J]. Virol J, 2010, 7:355.
[10] STORMS Z J, SAUVAGEAU D. Modeling tailed bacteriophage adsorption:Insight into mechanisms[J]. Virology, 2015, 485:355-362.
[11] HU B, MARGOLIN W, MOLINEUX I J, et al. The bacteriophage T7 virion undergoes extensive structural remodeling during infection[J]. Science, 2013, 339(6119):576-579.
[12] MONTAG D, HASHEMOLHOSSEINI S, HENNING U. Receptor-recognizing proteins of T-even type bacteriophages. The receptor-recognizing area of proteins 37 of phages T4 TuIa and TuIb[J]. J Mol Biol, 1990, 216(2):327-334.
[13] YAP M L, ROSSMANN M G. Structure and function of bacteriophage T4[J]. Future Microbiol, 2014, 9(12):1319-1327.
[14] RIEDE I, DREXLER K, SCHWARZ H, et al. Teven-type bacteriophages use an adhesin for recognition of cellular receptors[J]. J Mol Biol, 1987, 194(1):23-30.
[15] ZHANG C, LI W L, LIU W H, et al. T4-like phage Bp7, a potential antimicrobial agent for controlling drug-resistant Escherichia coli in chickens[J]. Appl Environ Microbiol, 2013, 79(18):5559-5565.
[16] ZHANG C, LI W H, REN H Y. Complete genome sequence of Bp7, an Escherichia coli bacteriophage with a wide host range[J]. J Virol, 2012, 86(24):13832.
[17] 齐心,陈培培,邹玲,等. 噬菌体Bp7穿孔素holin的克隆、表达及其活性分析[J]. 畜牧兽医学报, 2017, 48(12):2392-2398.
QI X, CHEN P P, ZOU L, et al. Cloning, expression and activity analysis of phage Bp7 holin[J]. Acta Veterinaria et Zootechnica Sinica, 2017, 48(12):2392-2398. (in Chinese)
[18] PIRES D P, MELO L, VILAS BOAS D, et al. Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections[J]. Curr Opin Microbiol, 2017, 39:48-56.
[19] LIN D M, KOSKELLA B, LIN H C. Phage therapy:An alternative to antibiotics in the age of multi-drug resistance[J]. World J Gastrointest Pharmacol Ther, 2017, 8(3):162-173.
[20] TROJET S N, CAUMONT-SARCOS A, PERRODY E, et al. The gp38 adhesins of the T4 Superfamily:A complex modular determinant of the phage's host specificity[J]. Genome Biol Evol, 2011, 3:674-686.
[21] DREXLER K, RIEDE I, MONTAG D, et al. Receptor specificity of the Escherichia coli T-even type phage Ox2:Mutational alterations in host range mutants[J]. J Mol Biol, 1989, 207(4):797-803. |